AMISTEM AND QUADRA - LINE EXTENSION

K121011 · Medacta International · LZO · Jun 8, 2012 · Orthopedic

Device Facts

Record IDK121011
Device NameAMISTEM AND QUADRA - LINE EXTENSION
ApplicantMedacta International
Product CodeLZO · Orthopedic
Decision DateJun 8, 2012
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 888.3353
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Medacta Total Hip Prosthesis System is intended for cementless use in total or partial hip arthroplasty and in primary or revision surgery. Hip replacement is indicated in the following cases: · Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid polyarthritis, or congenital hip dysplasia. · Avascular necrosis of the femoral head. · Acute traumatic fracture of the femoral head or neck. · Failure of previous hip surgery, joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement.

Device Story

Line extension of femoral stems for cementless total or partial hip arthroplasty; includes smaller sizes for patients with smaller bone structures and a collared version for axial stress transfer to proximal femur. Stems implanted by orthopedic surgeons in clinical/OR settings. Devices function as mechanical components of hip prosthesis system; provide structural support and fixation within femoral canal. Benefit: restoration of joint function and pain relief for patients with degenerative or traumatic hip conditions.

Clinical Evidence

Bench testing only. Compliance with ISO 7206-4 and ISO 7206-6 standards for fatigue and mechanical performance.

Technological Characteristics

Femoral stems made of titanium alloy (ISO 5832-11). Hydroxyapatite coating (ASTM F1185). Cementless fixation. Mechanical device; no software, electronics, or energy source.

Indications for Use

Indicated for patients requiring total or partial hip arthroplasty (primary or revision) due to arthritis, traumatic arthritis, rheumatoid polyarthritis, congenital hip dysplasia, avascular necrosis, acute traumatic fracture of femoral head/neck, or failure of previous hip surgery/reconstruction.

Regulatory Classification

Identification

A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ JUN - 8 2012 Image /page/0/Picture/2 description: The image shows the word "Medacta" in a simple, sans-serif font. The first letter, "M", is stylized with two triangles pointing upwards, creating a unique visual element. A horizontal line runs beneath the entire word, adding a subtle emphasis to the logo. The overall design is clean and modern, suggesting a professional and reliable brand. International ### 510(k) Summary Applicant/Sponsor: Medacta International SA Strada Regina 6874 Castel San Pietro (CH) Switzerland Phone (+41) 91 696 60 60 Fax (+41) 91 696 60 66 Contact Person: Mr. Adam Gross Director of Regulatory and Quality Medacta USA 4725 Calle Quetzal, Unit B Camarillo, CA, 93012 Phone: (805)437-7085 Fax: (805)437-7553 Email: AGross@medacta.us.com Date Prepared: 03/30/2012 #### DEVICE INFORMATION Trade/Proprietary Name: AMIStem and Quadra - Line Extension Common Name: Femoral Stem Classification Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis > 21 CFR 888.3353 Class II Device Product Codes: LZO, MEH Predicate Devices: K072857 - Medacta Total Hip Prosthesis System-Quadra S, CoCr Ball Heads, Medacta International K082792 - Quadra H; Quadra R, Medacta International K093944 - AMIStem H; Quadra S-H (SN), Medacta International AMIStem and Quadra - Line Extension 510(k) Section 5 - Page 2 of 4 {1}------------------------------------------------ #### Product Description The AMIStem and Quadra - Line Extension is comprised of the following femoral stems: - Quadra H STD #00 Short neck ● - Quadra S STD #00 Short neck . - AMIStem H STD Stem #00 ● - AMIStem H LAT Stem #0 - AMIStem H Collared STD and LAT, multiple sizes The subject devices have the same material as the predicate devices (titanium alloy, according to ISO 5832-11, 1994, Implants for surgery - Metallic materials - part 11: Wrought titanium 6-aluminum 7-niobium alloy). The AMIStem H and Quadra H have the same coating as the predicate devices: Hydroxyapatite coating, material according to ASTM F1185. The Quadra H STD #00 Short neck, Quadra S STD #00 Short neck, AMIStem H STD Stem #00, and AMIStem H LAT Stem #0 are a smaller size than the predicate devices and are intended for patients with a smaller bone structure. The AMIStem H Collared differs from the AMIStem H (KQ93944) only for the presence of the collar. The collar of the stem is designed to achieve contact only with the medial femoral cortex and to provide a path for direct axial stress transfer from the prosthesis to the proximal femur avoiding the over-insertion of the stem in case of subsidence. #### Indications for Use The Medacta Total Hip Prosthesis System is intended for cementless use in total or partial hip arthroplasty and in primary or revision surgery. Hip replacement is indicated in the following cases: - · Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid polyarthritis, or congenital hip dysplasia. - · Avascular necrosis of the femoral head. - · Acute traumatic fracture of the femoral head or neck. - · Failure of previous hip surgery, joint reconstruction, internal fixation, - arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement. Section 5 - Page 3 of 4 {2}------------------------------------------------ #### Comparison to Predicate Devices The intended use, materials, and performance characteristics for all of the femoral stems that are the subject of this submission are the same as the correspondent femoral stems already registered in the predicate devices. #### Performance Testing The AMIStem and Quadra - Line Extension was tested in accordance with ISO 7206-4 and ISO 7206-6. The subject devices did not raise any new issues of safety and effectiveness and are substantially equivalent to the predicate devices. #### Conclusion: Based on the above information, the AMIStem and Quadra - Line Extension can be considered as substantially equivalent to its predicate devices. #### AMIStem and Quadra - Line Extension 510(k) #### Section 5 - Page 4 of 4 {3}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/3/Picture/1 description: The image shows the logo for the Department of Health & Human Services (HHS). The logo features the department's name encircling a stylized symbol. The symbol consists of three curved shapes resembling a person embracing or supporting another, representing the department's mission of providing essential services and protecting the health of all Americans. #### Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002 Medacta International % Medacta USA Mr. Adam Gross Director of Regulatory and Quality 4725 Calle Quetzal, Unit B Camarillo, CA 93012 Re: K121011 Trade/Device Name: AMIStem and Quadra - Line Extension Regulation Number: 21 CFR 888.3353 Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis Regulatory Class: Class II Product Code: LZO, MEH Dated: May 8, 2012 Received: May 9, 2012 Dear Mr. Gross: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register_ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must JUN - 8 2012 {4}------------------------------------------------ #### Page 2 - Mr. Adam Gross comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely yours, Erin D. Keith +s Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ # Indications for Use 510(k) Number (if known): Device Name: AMIStem and Quadra - Line Extension Indications for Use: The Medacta Total Hip Prosthesis System is intended for cementless use in total or partial hip arthroplasty and in primary or revision surgery. Hip replacement is indicated in the following cases: · Severely painful and/or disabled joint as a result of arthritis, traumatic arthritis, rheumatoid polyarthritis, or congenital hip dysplasia. - · Avascular necrosis of the femoral head. - · Acute traumatic fracture of the femoral head or neck. - · Failure of previous hip surgery, joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip ·replacement. Prescription Use × (21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Devi e Evaluation (ODE) Asnt ﺘﺮ (Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices KIZIOII 510(k) Number . AMIStem and Quadra - Line Extension 510(k) March 30, 2012 Section 4 - Page 2 of 2
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from the tree

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...